Is Hemp Flower Legal? Legal Status 2026

Yes: flower from fibrous hemp in which the sum of delta-9-THC and THCA does not exceed 0.3% of dry mass is legal in Poland, and the government plan to ban its sale for smoking did not enter the law. Since July 2024, the Polish hemp industry has lived with one question: will selling CBD flower for smoking become a crime? The Ministry of Health’s bill, marked UD 85 in the legislative register, proposed a fine for selling fibrous hemp for purposes other than those listed in the law, such as industrial, food, or cosmetic, and imprisonment up to one year for selling in significant quantities or to minors. We reviewed the entire legislative process in the Government Legislation Center documents and parliamentary prints. The answer is clear: the provisions banning it were removed at the Standing Committee of the Council of Ministers stage, and the law passed on July 3, 2026, contains no trace of them. Below you will find the text of the withdrawn provisions, a timeline reconstruction, a description of the law that came into force on August 27, 2026, excise tax provisions, and practical conclusions for flower buyers.

KEY INFORMATION
• Flower with a sum of delta-9-THC and THCA up to 0.3% dry mass remains legal as fibrous hemp (Art. 4 point 5 of the Act, wording from Journal of Laws 2022 item 763).
• Government bill UD 85 wanted to punish selling flower for smoking and its advertising with fines, and selling in significant quantities or to minors with up to one year imprisonment.
• Provisions on trade in fibrous hemp disappeared from the bill in the text published on January 21, 2026.
• The July 3, 2026 Act (Journal of Laws 2026 item 1004) came into force on August 27, 2026, and does not concern flower sales.
• EFSA set in February 2026 a temporary safe intake level of CBD: about 2 mg daily for a 70 kg person.

Is hemp flower legal in Poland today?

Yes. Flower from industrial hemp in which the sum of delta-9-tetrahydrocannabinol and tetrahydrocannabinolic acid does not exceed 0.3% dry mass is fibrous hemp under Article 4 point 5 of the Anti-Narcotics Act of July 29, 2005 (consolidated text Journal of Laws 2023 item 1939). It is not a narcotic, so Article 62 of the Act on penalties for possession does not apply.

This threshold has applied since May 7, 2022. It was introduced by the Act of March 24, 2022, Journal of Laws 2022 item 763, raising the limit from the previous 0.2%. Note the second sentence of the definition, rarely mentioned: the sum is rounded to one decimal place. A batch with 0.34% fits the definition, but 0.35% does not. In disputes with authorities, this single digit decides the product’s classification.

The second threshold works the other way. Hemp herb other than fibrous hemp means any above-ground part of the plant, excluding seeds, containing more than 0.3% of the same sum. The boundary is sharp and set solely by lab results, not by appearance or smell.

The difference in consequences is drastic. Possession of narcotics contrary to the Act is punishable by imprisonment up to 3 years, or from 1 to 10 years for significant amounts, or a fine, restriction of liberty, or imprisonment up to 1 year for smaller amounts. Flower within the 0.3% limit is not a narcotic, so none of these apply.

The Act does not regulate the purpose for which the consumer uses legally purchased flower. This gap has justified selling flower as a collector’s item or for aromatherapy. It also became a point of contention for the bill described below.

Until September 2026, nothing changed in this structure despite two years of work on an amendment that would alter it. We rechecked the status described here on September 23, 2026, based on texts published in the Journal of Laws, Government Legislation Center documents, and parliamentary prints.

What exactly did the government bill UD 85 propose?

The bill did not explicitly say CBD flower is a narcotic. It worked more subtly: it closed the list of allowed purposes for trade, making everything else illegal. The effect for a hemp shop would be the same as listing flower as a narcotic, but without changing the definition in Article 4.

The December 30, 2024 version, available in the bill files at the Government Legislation Center, contained six related provisions. The core was the proposed Article 45 paragraph 8 stating: “Fibrous hemp and products made from it may be introduced into trade or used for financial gain only for the purposes specified in paragraphs 3 and 5.”

The bill also amended the definition of introduction into trade in Article 4 point 34, adding fibrous hemp and products made from it. Without this correction, the other provisions would have nothing to prohibit, as the previous definition covered only narcotics, psychotropic substances, precursors, and new psychoactive substances.

Notably, the bill did not change the 0.3% threshold, did not move flower to the narcotics list, and did not alter the definition of fibrous hemp. Flower would remain an agricultural product, but selling it for smoking would become prohibited. This distinction is important: the consumer would not be liable for possession, only the seller for selling.

The bill’s author provided a six-month vacatio legis for this part of the regulation to allow shops to sell off stock. The rest of the changes would come into force 14 days after promulgation.

What was the Ministry of Health’s reasoning?

One word: “consumption.” The bill’s justification assumed that cultivation of fibrous hemp for food purposes is legal, but inhaling by combustion or without combustion is not consumption. The authors even cited the PWN dictionary definition, where to consume means to introduce food through the mouth into the stomach.

From this, the conclusion was that smoking and vaporizing are use, not consumption, so cultivation for such purposes is outside the allowed list. Article 45 paragraph 3 of the current Act lists five groups of cultivation purposes for fibrous hemp.

• Textile, chemical, cellulose-paper, cosmetic, pharmaceutical, and energy needs
• Seed production and scientific research
• Breeding fibrous hemp varieties and land reclamation and remediation
• Food, veterinary, feed, beekeeping, fertilizing, insulating purposes
• Production of composite materials, building materials, and natural plant protection agents

Smoking is not on this list and never has been. The proposed Article 45 paragraph 8 would not add a direct ban but would close the catalog from the trade side.

The justification called this a normative deficit. The authors noted that only selling would be punishable, not use. Offering flower to a friend socially would be outside penalization, as such acts have little or no social harm.

The justification also addressed cross-border trade. The authors wrote that the gap results in consumers buying products of unknown origin abroad that may cause intoxication and addiction. The advertising ban in Article 20a was to close this loophole. The provision would cover advertising visible to users with a Polish IP address, regardless of server location.

The bill’s author explicitly counted on an educational effect. The justification stated that new types of prohibited acts would start shaping legal awareness and reduce interest in these substances among current consumers. The argument was based not only on health protection but also on changing attitudes.

We noted something missed in press comments: the proposed Article 45 paragraph 8 would also cover products outside flower and e-liquids. The justification explicitly mentioned future forms of administration, e.g., injection or nasal inhalation.

When did the ban provisions disappear from the bill?

In the text published on January 21, 2026. The bill then returned to the Standing Committee of the Council of Ministers as a new text, already without provisions regulating trade in fibrous hemp. Since the first version in July 2024, there had been a year and a half of interdepartmental consultations, opinions, and public consultations.

Comments came from the Ministry of Infrastructure, Ministry of Finance, Ministry of Internal Affairs and Administration, Government Legislation Center, Ministry of National Defense, Ministry of Agriculture and Rural Development, and Ministry of Justice. The RCL files contain dozens of such positions, some dated May and June 2025.

The bill’s status in the Ministry of Health’s register remains open, with the latest modification dated July 7, 2026, under the Standing Committee tab. Open status does not mean the process continues: further proceedings moved to the Sejm and ended there.

It is worth comparing these dates with what was written about the matter then. Articles describing the bill as a current threat appeared in spring 2026, although the provisions disappeared from the text sent forward in January. The gap between public discourse and legislative status was several months.

The original version of this article described the status as of April 25, 2026, and spoke of future bans. By that date, provisions on fibrous hemp trade no longer existed, and five days later the bill without them was submitted to the Sejm. We correct this directly because in legal texts the date of status is part of the content, not decoration.

What does the July 3, 2026 Act really change?

Mainly provisions on addiction treatment, trade in narcotics in medical entities, and agricultural formalities. The text published in Journal of Laws 2026 item 1004 contains no word “advertising,” “inhaling,” or provisions on significant quantities of fibrous hemp.

We checked the full text for the six provisions from the table above. None survived. Articles 20a, 65a, and 68a simply do not exist in the published version. Curiously, Article 45 paragraph 8 was reused but with completely different content than in the bill.

The main weight of the amendment lies outside agriculture. The Act expands access to treatment for addicted persons and simplifies procedures for public institutions. It also organizes medical aid abroad, e.g., during natural disasters, and reporting to the Chief Pharmaceutical Inspector.

One noteworthy criminal provision change: Article 57 paragraph 2 was amended to provide imprisonment up to 3 years for preparation of crimes under Articles 53 paragraph 2, 55 paragraph 3, and 56 paragraph 3. This concerns manufacture and trade in narcotics, not fibrous hemp.

The Act came into force 30 days after promulgation, i.e., August 27, 2026. It does not provide a separate longer vacatio legis for trade, as there is nothing left to postpone.

Who does the Act effective August 27, 2026, concern?

Primarily farmers and purchasing points, not consumers. Changes concern deadlines, scope of controls, and administrative penalties in the fibrous hemp registry maintained by the National Agricultural Support Center. If you buy flower in a shop, nothing changed for you after August 27, as sellers gained no new obligations.

The group is larger than suggested by cultivation area. According to KOWR data published October 21, 2025, the number of producers in the registry nearly quadrupled in four years, from 425 to 1606. The area grew much slower and has been practically stable since 2023. The number of small, few-hectare plantations is growing, not the size of individual farms.

Cultivation shifted geographically. In 2022, Lower Silesian and Greater Poland voivodeships dominated; in 2025, Lublin, Masovian, and Warmian-Masurian lead. For flower buyers, the simple conclusion is: domestic raw material is available, and sellers should be able to indicate their source.

The limit for own-use cultivation remains unchanged at 1 hectare per year. The new definition in Article 45 paragraph 9 clarifies that such cultivation serves to obtain products used on the farm, without resale. Paragraph 8 defines own processing as processing yield from own crops with intent to sell processed products.

This distinction matters for small farms. A farmer harvesting and selling raw material and one processing and selling finished products were previously judged by practice. Since August 27, 2026, both have statutory definitions, which should reduce disputes during inspections.

A 10,000 PLN fine for obstructing control of purchasing entities is a new instrument. Previously, sanctions mainly concerned unlawful cultivation and discrepancies in reported area; blocking control had no specific penalty.

Is CBD psychoactive?

Not in the sense THC is: cannabidiol does not stimulate the CB1 receptor, so it does not cause intoxication, impair psychomotor skills, or produce an effect that could be called being under influence. In a broader sense, including any effect on the central nervous system, cannabidiol has activity, as clinical studies showed it reduces anxiety and seizure frequency. Both statements are true but refer to different things.

The distinction has legal consequences. The statutory limit in Poland is set by THC content, not cannabidiol properties, so the debate on whether CBD is psychoactive does not affect trade. The decisive factor is the 0.3% threshold of the sum of delta-9-THC and THCA in dry mass.

One caveat on sources: Polish texts usually cite the 2018 WHO report to support lack of psychoactivity. We could not access the full committee report at the source, so the above statements rely on clinical data and the provision’s wording. The WHO statement from that meeting, cited below in the section on whether science considers CBD a narcotic, is verifiable.

How does EU law limit national CBD bans?

By the principle of free movement of goods. The Court of Justice of the EU ruled on November 19, 2020, in case C-663/18, known as Kanavape, that Articles 34 and 36 TFEU oppose national bans on CBD legally produced in another member state unless a real public health risk is demonstrated.

The Court also rejected the claim that CBD extracted from the whole hemp plant is a narcotic under the 1961 Single Convention. It justified this by the lack of psychoactive properties confirmed by available scientific knowledge.

This shield has clear limits rarely discussed in Poland. The ruling protects goods brought from another EU country, not goods produced and sold entirely in Poland. The state retains the right to restrictions if it presents a reliable risk assessment and chooses a proportionate measure. The Court noted that the French ban would not cover synthetic CBD with the same properties and that if a national court confirmed this, it would indicate inconsistency.

The case concerned e-cigarette oil made in the Czech Republic from the whole hemp plant and sold in France, where law allowed only fiber and seeds. The Court found the French ban equivalent to a quantitative restriction, which Article 34 TFEU excludes.

It also resolved a technical issue relevant in subsidy disputes. Regulations 1307/2013 and 1308/2013, governing direct payments and common agricultural market organization, do not apply to national measures banning CBD sales. Agricultural law arguments will not work in trade ban disputes.

A member state may still invoke Article 36 TFEU restrictions but must base them on risk assessments using the most reliable scientific data. Mere uncertainty about safety is insufficient evidence of harm.

If UD 85 had entered into force as originally drafted, a dispute over compliance with Article 34 TFEU would be almost certain. The construction based on purpose of use, not chemical composition, would also cover flower legally imported from Czechia or Germany.

What CBD flower is and how it differs from marijuana is explained in a separate guide.

What did EFSA rule on CBD safety in 2026?

That data are still lacking but for the first time it gave a number. The EFSA Nutrition Panel set on February 9, 2026, a temporary safe intake level of CBD at 0.0275 mg per kilogram body weight per day, about 2 mg for a 70 kg adult (EFSA Journal, 2026). The value was derived by benchmark dose method with an uncertainty factor of 400 and applies only to supplements with at least 98% pure cannabidiol, without nanoparticles.

The panel closed its opinion with a statement that must be read with this number: safety cannot be established for persons under 25 years old, pregnant and breastfeeding women, and those taking medications. This is not a marginal note but a conclusion alongside the dose, covering three groups that include a large part of readers.

This updates the 2022 opinion, where the panel could not identify a no observed adverse effect level among 19 applications. A literature review to June 2024 confirmed gaps remain due to short study durations, non-standardized protocols, and concomitant medication use.

Four years ago, the panel explicitly noted missing data on CBD’s effect on drug metabolism, toxicokinetics in various matrices, half-life, and accumulation. The order matters. Until these data exist, authorization remains suspended regardless of market size.

What specific gaps did EFSA identify?

Liver, nervous system, hormones, and reproduction, with the strongest signal from animal studies. The panel’s conclusions are cautious because data in each of these four areas are either animal, short-term, or from subjects taking medications.

Animal studies showed repeatable liver toxicity, with liver mass and histopathological changes as the most sensitive endpoints. Human studies indicated hepatotoxic potential, especially when combining CBD with drugs. Neurological and psychiatric safety data were insufficient, and CBD’s ability to cross the placenta was a reason for caution.

The panel also described hormonal disturbances observed in animals, including thyroid hormone changes, and neurodevelopmental effects after prenatal exposure, which were long-lasting and sex-dependent. Reproductive toxicity returned as a point needing more data.

Bioavailability is a separate issue. Pharmacokinetic studies confirmed CBD absorption varies by matrix and whether taken with food. This variability complicates extrapolating results from one study to another product and explains why the panel set a temporary, not final, level.

This assessment concerns CBD as a food ingredient under Regulation 2015/2283 on novel foods. Hemp flower is not sold as food in Poland, so formally it is outside this scope. Advocates of stricter regulation still cite these gaps as evidence of risk.

Does science consider CBD a narcotic?

No. The WHO Expert Committee on Drug Dependence at its 40th meeting in June 2018 recommended that preparations recognized as pure CBD not be subject to international narcotics control. The rationale was lack of psychoactive properties and no abuse or dependence potential (WHO, 2018).

The 2017 review by Iffland and Grotenhermen, one of the most cited on CBD safety, confirmed a favorable adverse effect profile compared to drugs used in epilepsy and psychotic disorders (Cannabis and Cannabinoid Research, 2017). Most reported were fatigue, diarrhea, and changes in appetite and weight.

The same review noted areas needing study: CBD’s effect on liver enzymes, drug transporters, and hormonal balance. The authors stressed a lack of large, long-term studies.

WHO’s recommendation had procedural consequences. The session was convened specifically to assess cannabis and related substances, with results announced at a press conference in September that year. Conclusions were forwarded to the UN Narcotics Commission for classification decisions.

The Kanavape case court relied on a similar premise. Since available knowledge does not indicate psychotropic effects, CBD does not fit the narcotic definition in the 1961 Convention. The alignment of public health authority and EU court positions is a strong argument against classifying cannabidiol itself as a narcotic. The distinction between psychoactive and intoxicating substances is explained in a separate article: Is CBD non-psychoactive?.

Quality of evidence on benefits is a separate matter. EFSA noted most human data come from studies on Epidyolex at therapeutic doses, where adverse effects are accepted due to benefit. This balance does not apply to food, so the same studies have less evidential value.

It is useful to distinguish two questions often conflated in public debate. WHO answered whether CBD requires international narcotics control and said no. EFSA answers how much CBD can be safely eaten daily and says data are insufficient. A negative answer to the first does not determine the second.

Can CBD flower cause a positive drug test?

It can, but THC present in full-spectrum products, not CBD itself, is responsible. Standard immunoassays detect the THC-COOH metabolite, which pure CBD does not produce. What matters is what accompanies cannabidiol in the product.

The best data come from Spindle et al. 2020 (Journal of Analytical Toxicology), where six healthy adults underwent all administration variants. After 100 mg pure CBD orally or by vaporization, only 1 of 218 urine samples screened positive at 20 ng/ml cutoff, and none confirmed at 15 ng/ml. After vaporizing CBD-rich flower containing 3.7 mg THC, nine samples screened positive, four confirmed by LC-MS-MS. The authors concluded a single dose of pure CBD does not yield a positive workplace test, but products with THC admixture can.

With longer use, the percentage rises. In an open study by Dahlgren et al. published in JAMA Psychiatry, participants took a full-spectrum product averaging 34.7 mg CBD and 0.8 mg THC daily for four weeks. After this, 7 of 14 tested positive for THC-COOH, exactly half, though none reported psychoactive effects. The product contained 0.02% delta-9-THC by weight; the 0.3% threshold applies to the plant, not oil.

CBD concentrations in urine are sometimes confused with THC. After oral administration, mean peak was 776 ng/ml; after vaporization, 261 ng/ml. Standard drug tests do not detect these because they target a different compound. Also remember the difference between screening and confirmatory tests: immunoassays work at 20, 50, or 100 ng/ml cutoffs and give preliminary results; confirmation by chromatography at 15 ng/ml is decisive. We covered this separately in Does CBD show on drug tests?.

The conclusion for flower users is simple and not very comforting. THC metabolite accumulates with daily use, so a one-day break before testing does little. In Dahlgren et al., positive results correlated only with creatinine concentration, not age or dose. If subject to sobriety tests, CBD isolate carries less risk than flower or full-spectrum oil.

Is hemp flower subject to excise tax?

The Excise Tax Act does not name hemp flower explicitly but has a provision on products made from plants other than tobacco. Products “consisting wholly or partly of substances other than tobacco but otherwise meeting cigarette or smoking tobacco criteria” are “treated as cigarettes and smoking tobacco” (Art. 98 para. 8, consolidated text Journal of Laws 2026 item 412).

These criteria are in the same article. Smoking tobacco is defined as tobacco “cut or otherwise divided, twisted or pressed into blocks and suitable for smoking without further industrial processing” (Art. 98 para. 5), and cigarettes as rolled tobacco suitable for smoking in that form (Art. 98 para. 2). An exception applies to products containing no tobacco and used solely for medical purposes: these are not treated as tobacco products (Art. 98 para. 8 second sentence).

Whether a product meets these criteria is assessed by the tax authority, not by packaging description. We do not provide our interpretation of this provision for fibrous hemp flower. If a seller claims the product is “with excise” or “without excise,” ask for the basis of this information.

How to buy flower so documentation protects you during inspection?

Collect three things: batch test result, proof of purchase, and original packaging. An officer cannot distinguish fibrous hemp flower from herb of non-fibrous hemp on the spot, as the boundary is set solely by lab results. Documents shorten the path to clarifying the matter.

• Analytical certificate of the batch showing the sum of delta-9-THC and tetrahydrocannabinolic acid, not just delta-9-THC, as the legal definition counts both together.
• Batch number on packaging matching the certificate number; otherwise, the document proves nothing.
• Proof of purchase with product name and seller data, preferably an invoice retained in the seller’s system.
• Strain name from the EU hemp variety catalog, allowing linking the product to legal cultivation.
• Producer data registered in the fibrous hemp registry, which the seller should provide on request.

Beware of documents that do not identify a specific batch. Such files sometimes circulate among offers from different sellers and say nothing about the product in your hands. When buying hemp flower, ask for the result for a specific batch before purchase, not after. A separate set of documents applies to patients with prescriptions, described in the article on police inspection and medical marijuana.

Read the certificate from the header, not the results table. It should indicate the testing laboratory, sample collection date, and batch identifier. Only then look at numbers, as a result without these three elements cannot be linked to a specific product.

Also check what the sample concerned. The legal limit applies to flower or fruiting tops from which resin was not removed, i.e., the richest cannabinoid part. Results from leaf testing or whole biomass mixtures will be lower and do not answer the question posed in the definition.

Note whether the lab reported delta-9-THC alone or the sum with tetrahydrocannabinolic acid. Many chromatographic methods decarboxylate the sample during analysis and report total THC, but this is not universal. The legal definition requires the sum, so a certificate with only delta-9-THC does not directly answer the authority’s question.

Storage method also matters for evidence. Flower transferred to an unmarked jar loses connection with label and certificate. How to store material without quality loss is covered in the guide on storing flower.

What to watch to not miss a new ban?

Three places: Journal of Laws, legislative register, and parliamentary prints. The UD 85 history showed that fate of provisions is decided at the government stage, not parliamentary. Provisions on flower disappeared before the bill even reached the Sejm, so tracking votes alone would not warn.

A private member’s bill to amend the Anti-Narcotics Act (print no. 2672) was submitted March 27, 2026, and referred to first reading in committees on June 11, 2026; by September 23, 2026, it had not progressed. It concerns decriminalization of possession of small amounts of non-fibrous hemp herb and cultivation of one plant for personal use. It does not cover fibrous hemp flower but will show legislative attitude direction. A government bill amending the Tobacco Act (print no. 2362, also before first committee reading) proposes banning disposable e-cigarettes and nicotine products outside that Act; flower without nicotine is unaffected.

The second thread is novel food procedure. CBD applications have been with EFSA since 2019, and the February 2026 opinion set a temporary intake level, not authorization. EU-level decisions will affect oils and foods, not flower, but food arguments often recur in Polish bills.

To check legal status, two addresses suffice. The eli.gov.pl portal shows the promulgated text with promulgation and entry into force dates; for fictitious acts, it simply does not open the page. The Government Legislation Center shows successive bill versions with dates, allowing you to see when a provision appeared and when it was removed.

Our advice from this reconstruction: compare versions, not headlines. The difference between the December 30, 2024 version and the January 21, 2026 text is six provisions simply missing, and no press summary will show this as clearly as two files side by side.

Fair to add the matter is fluid. We rechecked the status on September 23, 2026. A new bill may appear in any minister’s legislative register at any time, and a one-time removal of provisions does not mean they will not return under another number and justification.

Frequently Asked Questions

Is hemp flower legal in Poland?

Yes, as of September 2026. Industrial hemp in which the sum of delta-9-THC and tetrahydrocannabinolic acid does not exceed 0.3% dry mass is fibrous hemp under Article 4 point 5 of the Anti-Narcotics Act. The government bill that aimed to change this lost the relevant provisions before submission to the Sejm.

Does the July 3, 2026 Act ban the sale of CBD flower?

No. The text published in the Journal of Laws under position 1004 does not include the proposed Article 20a banning advertising, nor Article 65a on imprisonment, nor Article 68a. The Act came into force on August 27, 2026, and mainly amends cultivation and addiction treatment provisions.

What exactly did the UD 85 bill propose?

The proposed Article 45 paragraph 8 allowed trade in fibrous hemp only for purposes listed in paragraphs 3 and 5, including industrial, food, and cosmetic. Selling flower for smoking would be a misdemeanor punishable by a fine (Article 65 paragraph 1 point 3), and in significant quantities or to minors a crime punishable by up to one year imprisonment (Article 65a).

Who caused the provisions on flower to be removed?

The provisions disappeared at the Standing Committee of the Council of Ministers stage. The new text was published in the RCL on January 21, 2026. This was preceded by ministry comments during consultations and public consultations from July 2024 to July 2025 involving industry organizations.

Can CBD flower cause a positive drug test?

It can, but THC present in full-spectrum products, not CBD itself, is responsible. In the study by Spindle et al., after pure CBD only 1 of 218 urine samples screened positive. In Dahlgren et al., after four weeks of full-spectrum product use, 7 of 14 participants tested positive.

Does EU law protect the Polish CBD market from bans?

Partially. The CJEU ruling of November 19, 2020, in case C-663/18 prohibits blocking CBD legally produced in another member state without demonstrating a real health risk. However, it does not protect against national regulations covering only goods produced and sold in Poland.

How much CBD daily does EFSA consider safe?

In February 2026, the NDA panel set a temporary safe intake level at 0.0275 mg per kilogram body weight per day, about 2 mg for a 70 kg adult. This applies to CBD as a food ingredient, not flower. Safety cannot be established for persons under 25 years old, pregnant or breastfeeding women, or those taking medications.

What documents should you have when buying flower?

Analytical certificate of the batch showing the sum of delta-9-THC and THCA, proof of purchase with product name, and original packaging with strain designation. The seller should also indicate the producer registered in the fibrous hemp registry maintained by the National Agricultural Support Center.

Devices for heating flower without combustion can be found in the vaporizers category.

This article is for informational and educational purposes and does not constitute legal advice. The legal status described applies as of the update date, and hemp regulations may change. Consult a lawyer or current legal acts before making decisions.

Author: Michał Waluk · Published: 2026-05-10 · Updated: 2026-09-23